Biotech Stocks Rally on AI Potential

Biotech stocks surged in June, driven by analyst optimism around AI-driven drug discovery. On June 4, Leerink initiated coverage on Absci Corporation (ABSI) with an 'Outperform' rating, citing its AI-native clinical-stage pipeline. Denali Therapeutics (DNLI) and Crinetics Pharmaceuticals (CRNX), both AI-driven biotechs, also garnered bullish attention, with Denali halting a joint project with Biogen on May 22. AbCellera Biologics (ABCL) and SOPHiA GENETICS (SOPH), two healthcare AI stocks, were also highlighted by analysts, with BTIG raising SOPH's price target to $8 on April 15.

The rally in biotech stocks, particularly those leveraging AI, impacted the broader healthcare and biotechnology sectors. Investors rotated into AI-driven drug discovery platforms, pushing up share prices and driving increased trading volumes. The positive analyst sentiment also led to a repricing of valuation multiples, with target prices for these stocks rising.

Looking ahead, investors should watch for Absci's (ABSI) clinical updates, expected in Q3 2023, and Denali's (DNLI) progress on its pipeline, with a phase 1 readout for DNL151 anticipated in Q4 2023. Additionally, AbCellera's (ABCL) ABCL635 candidate's safety data, expected in late 2023, could further validate the AI-driven biotech thesis.